Financial Performance - The company's operating revenue for 2023 was ¥302,800,718.15, a decrease of 25.51% compared to the previous year[3] - Net profit attributable to shareholders was ¥16,126,507.82, down 69.33% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,557,755.37, a decline of 90.91% compared to the previous year[4] - Basic earnings per share decreased to ¥0.1667, down 75.72% year-on-year[3] - Total assets at the end of the reporting period were ¥733,204,824.36, a decrease of 9.16% from the beginning of the period[4] - The company's equity attributable to shareholders increased by 0.06% to ¥601,519,972.36[4] Revenue Decline Factors - The decline in revenue was primarily due to a slowdown in emergency procurement in the medical and biopharmaceutical sectors and a strategic exit from low-margin C-end businesses[5] - Government subsidies received in 2023 were significantly lower than in 2022, impacting net profit[5] Research and Development - The company has made significant R&D investments, achieving breakthroughs in efficient refrigeration technology and new product development[5] - The company is focusing on diversifying its product strategy in the biomedical field through technological advancements[5]
中科美菱(835892) - 2023 Q4 - 年度业绩